Xencor reports $611M cash; outlines 2026 pipeline milestones for XmAb candidates

Xencor Inc

Unaudited cash, equivalents & marketable debt securities ~$611M as of Dec 31, 2025 vs $706.7M a year ago.
Cash expected to fund operations through 2028 based on current plans.
XmAb819 (ENPP3xCD3) for ccRCC: 25% partial response; pivotal study planned in 2027.
XmAb541 (CLDN6xCD3) for gynecologic/germ cell tumors: confirmed partial responses in 3 of 9 patients; pivotal study planned in 2027.
Autoimmune pipeline: Phase 1b plamotamab in RA, Phase 1 XmAb657 in IIM, Phase 2b XENITH-UC, and first-in-human TL1AxIL23p19 in 2H26.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.